# Pharmacokinetics and Safety, Tolerability of DWJ211in Healthy Volunteers

> **NCT04159961** · PHASE1 · COMPLETED · sponsor: **Daewoong Pharmaceutical Co. LTD.** · enrollment: 18 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** DWJ211

## Key facts

- **NCT ID:** NCT04159961
- **Lead sponsor:** Daewoong Pharmaceutical Co. LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-24
- **Primary completion:** 2020-04-21
- **Final completion:** 2020-04-21
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2024-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04159961

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04159961, "Pharmacokinetics and Safety, Tolerability of DWJ211in Healthy Volunteers". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04159961. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*